Published in:
Open Access
01-11-2010 | Poster presentation
Efficacy of adalimumab in sarcoidosis
Authors:
LSJ Kamphuis, W K Lam-Tse, W A Dik, J Bastiaans, P van Biezen, PLA van Daele, D J Kwekkeboom, RWAM Kuijpers, G S Baarsma, P M van Hagen, H Hooijkaas, JAM van Laar
Published in:
Journal of Translational Medicine
|
Special Issue 1/2010
Login to get access
Excerpt
Adverse effects and lack of specificity often hamper the use of conventional immunosuppressives in patients with systemic sarcoidosis. Adalimumab, a monoclonal antibody directed against the key cytokine involved in sarcoidosis, TNF-α, is used in patients with various immunological disorders [
1]. Improved specificity, hence less adverse effects are the major advantages of this new class of drugs leading to an exponentially increasing role in their clinical use. However, few reports involving adalimumab in patients with sarcoidosis have been published so far and are restricted to case reports. …
